Retagliptin

Retagliptin
Identifiers
  • Methyl 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H18F6N4O3
Molar mass464.368 g·mol−1
3D model (JSmol)
  • COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
  • InChI=1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3/t10-/m1/s1
  • Key:WIIAMRXFUJLYEF-SNVBAGLBSA-N

Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes.[1][2][3]

In 2023, it was approved in China by the National Medical Products Administration for blood glucose control for adult patients with type 2 diabetes.[4]

References

  1. ^ Meng, Xiangjun; Cai, Lanlan; Ren, Tianming; Sun, Dong; Gu, Jingkai (2018). "Simultaneous quantitative analysis of retagliptin and its main active metabolite in human multiple matrices by liquid chromatography tandem mass spectrometry". Analytical Methods. 10 (18): 2108–2114. doi:10.1039/C8AY00040A. ISSN 1759-9679.
  2. ^ Hu, Chao; Zheng, Jing; Miao, Jia; Liu, Fang; Hu, Ting-Ting; Gu, Jing-Kai; Shu, Shi-Qing; Wang, Ying; Zhu, Xiao-Hong; Liang, Mao-Zhi (2018). "[Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction]". Sichuan da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition. 49 (1): 74–80. ISSN 1672-173X. PMID 29737094.
  3. ^ Cahn, Avivit; Cernea, Simona; Raz, Itamar (2016). "An update on DPP-4 inhibitors in the management of type 2 diabetes". Expert Opinion on Emerging Drugs. 21 (4): 409–419. doi:10.1080/14728214.2016.1257608. PMID 27809608. S2CID 45825587.
  4. ^ "Retagliptin Phosphate Tablets Approved for Marketing by NMPA". National Medical Products Administration. 2023-06-28.